{"id":"abvd-and-radiotherapy","safety":{"commonSideEffects":[{"rate":"50-60%","effect":"Peripheral neuropathy"},{"rate":"30-40%","effect":"Fatigue"},{"rate":"20-30%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Brentuximab vedotin is an antibody-drug conjugate that binds to CD30, a protein expressed on the surface of certain cancer cells, and delivers a cytotoxic agent to these cells.","oneSentence":"Brentuximab vedotin targets CD30","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:20:29.974Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hodgkin lymphoma"},{"name":"Systemic anaplastic large cell lymphoma"}]},"trialDetails":[{"nctId":"NCT05675410","phase":"PHASE3","title":"A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-05-11","conditions":"Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8","enrollment":1875},{"nctId":"NCT03407144","phase":"PHASE2","title":"Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-04-09","conditions":"Hodgkin Lymphoma","enrollment":340},{"nctId":"NCT04685616","phase":"PHASE3","title":"Brentuximab Vedotin in Early Stage Hodgkin Lymphoma","status":"RECRUITING","sponsor":"University College, London","startDate":"2022-04-14","conditions":"Hodgkin Lymphoma","enrollment":1042},{"nctId":"NCT00005584","phase":"PHASE3","title":"Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"1998-10","conditions":"Lymphoma","enrollment":1649},{"nctId":"NCT03500133","phase":"PHASE4","title":"Pediatric Hodgkin Lymphoma Treatment Trial With Low Cumulative Doses of Chemotherapy Agents and Reduced Radiation.","status":"RECRUITING","sponsor":"Hospital JP Garrahan","startDate":"2017-10-06","conditions":"Pediatric Hodgkin's Disease","enrollment":500},{"nctId":"NCT03712202","phase":"PHASE2","title":"Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2018-11-28","conditions":"Ann Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage I Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage I Nodular Sclerosis Classic Hodgkin Lymphoma","enrollment":155},{"nctId":"NCT06263530","phase":"","title":"Prognostic Significance of ctDNA in HL","status":"RECRUITING","sponsor":"Interni hematologicka klinika FNKV","startDate":"2022-01-02","conditions":"Prognostic Cancer Model","enrollment":500},{"nctId":"NCT00003389","phase":"PHASE3","title":"Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"1999-06-17","conditions":"Lymphoma","enrollment":854},{"nctId":"NCT01390584","phase":"PHASE2","title":"Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma","status":"TERMINATED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2013-05-24","conditions":"Lymphoma","enrollment":6},{"nctId":"NCT05410314","phase":"","title":"Nutritional Supplement Based on Myo-inositol-D-chiro-inositoln in Long-term Survivors of Lymphoma","status":"COMPLETED","sponsor":"University of Bari Aldo Moro","startDate":"2020-02-07","conditions":"Lymphoma, Hodgkin, Menstrual Irregularity, Fertility Disorders","enrollment":90},{"nctId":"NCT01118026","phase":"PHASE2","title":"Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2010-09","conditions":"Lymphoma","enrollment":101},{"nctId":"NCT00992030","phase":"PHASE3","title":"R-ABVD vs ABVD-RT in Early Stage Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"Fondazione Michelangelo","startDate":"2009-09","conditions":"Hodgkin Lymphoma","enrollment":112},{"nctId":"NCT02298283","phase":"PHASE2","title":"Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD","status":"COMPLETED","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2015-04","conditions":"Hodgkin Lymphoma","enrollment":40},{"nctId":"NCT00433433","phase":"PHASE3","title":"Fludeoxyglucose F 18 PET Scan-Guided Therapy or Standard Therapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma","status":"UNKNOWN","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2006-10","conditions":"Lymphoma","enrollment":1952},{"nctId":"NCT00736320","phase":"PHASE3","title":"HD16 for Early Stage Hodgkin Lymphoma","status":"UNKNOWN","sponsor":"University of Cologne","startDate":"2009-11","conditions":"Hodgkin Lymphoma","enrollment":1150},{"nctId":"NCT00002561","phase":"PHASE3","title":"Radiation Therapy and Chemotherapy in Treating Patients With Hodgkin's Disease","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"1994-01-25","conditions":"Hodgkin Lymphoma","enrollment":405},{"nctId":"NCT01356680","phase":"PHASE3","title":"HD17 for Intermediate Stage Hodgkin Lymphoma","status":"COMPLETED","sponsor":"University of Cologne","startDate":"2012-01-13","conditions":"Hodgkin Lymphoma","enrollment":1100},{"nctId":"NCT00784537","phase":"PHASE2, PHASE3","title":"High-dose Chemotherapy and Stem Cell Transplantation, in Patients PET-2 Positive, After 2 Courses of ABVD and Comparison of RT Versus no RT in PET-2 Negative Patients","status":"COMPLETED","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2008-09","conditions":"Hodgkin's Lymphoma","enrollment":520},{"nctId":"NCT01399931","phase":"","title":"Dual Point PET Scan in Early Stage Hodgkin Lymphoma Patients With Bulky Lesions","status":"UNKNOWN","sponsor":"Ospedale Santa Croce-Carle Cuneo","startDate":"2012-01","conditions":"Hodgkin's Lymphoma","enrollment":150},{"nctId":"NCT01251107","phase":"PHASE3","title":"Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Fondazione Michelangelo","startDate":"2000-03","conditions":"Hodgkin Lymphoma","enrollment":331},{"nctId":"NCT00004010","phase":"PHASE2","title":"Combination Chemotherapy and Radiation Therapy in Treating Children With Previously Untreated Stage II, Stage III, or Stage IV Hodgkin's Disease","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"1999-10","conditions":"Lymphoma","enrollment":99},{"nctId":"NCT00003421","phase":"PHASE3","title":"Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Disease","status":"COMPLETED","sponsor":"Medical Research Council","startDate":"1998-06","conditions":"Lymphoma","enrollment":800},{"nctId":"NCT00041210","phase":"PHASE3","title":"Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Hodgkin's Lymphoma","status":"UNKNOWN","sponsor":"Mount Vernon Cancer Centre at Mount Vernon Hospital","startDate":"2001-10","conditions":"Lymphoma","enrollment":850},{"nctId":"NCT01468740","phase":"PHASE2","title":"Prospective Study on HIV-related Hodgkin Lymphoma","status":"UNKNOWN","sponsor":"Harlachinger Krebshilfe e.V.","startDate":"2004-03","conditions":"HIV-associated Hodgkin Lymphoma","enrollment":130},{"nctId":"NCT00264953","phase":"PHASE3","title":"HD11 for Intermediate Stages","status":"COMPLETED","sponsor":"University of Cologne","startDate":"1998-05","conditions":"Hodgkin´s Lymphoma","enrollment":1395},{"nctId":"NCT00970385","phase":"PHASE3","title":"Study About Treatment of Newly Diagnosed Non Cutaneous Peripheral T Cell Lymphoma","status":"COMPLETED","sponsor":"University Hospital, Grenoble","startDate":"1995-01","conditions":"Peripheral T Cell Lymphoma","enrollment":95},{"nctId":"NCT00188149","phase":"PHASE4","title":"Optimization of the Primary Therapy for Patients With Hodgkin's Disease and Evaluation of PET","status":"UNKNOWN","sponsor":"University Hospital Carl Gustav Carus","startDate":"2000-05","conditions":"Hodgkin Disease","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":89,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ABVD and Radiotherapy","genericName":"ABVD and Radiotherapy","companyName":"Fondazione Italiana Linfomi - ETS","companyId":"fondazione-italiana-linfomi-ets","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Brentuximab vedotin targets CD30 Used for Hodgkin lymphoma, Systemic anaplastic large cell lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}